Sort   by:  
 Page size 
UnknownMulticenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
Not available
S-EPMC4417726 | biostudies-literature
UnknownHealth-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.
Not available
S-EPMC6366953 | biostudies-literature
UnknownEmerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Not available
S-EPMC7696369 | biostudies-literature
UnknownNovel immunotherapy strategies for treatment of neuroendocrine neoplasms.
Not available
S-EPMC7530319 | biostudies-literature
UnknownAnalysis of the immune landscape of small bowel neuroendocrine tumors.
Not available
S-EPMC7787268 | biostudies-literature
UnknownTargeted radionuclide therapy in endocrine-related cancers: advances in the last decade.
Not available
S-EPMC10694449 | biostudies-literature
Unknown177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.
Not available
S-EPMC7227421 | biostudies-literature
UnknownSomatostatin receptor radionuclide therapy in neuroendocrine tumors.
Not available
S-EPMC8118168 | biostudies-literature
UnknownMolecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.
Not available
S-EPMC8385643 | biostudies-literature
UnknownBiomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.
Not available
S-EPMC10854756 | biostudies-literature
Sort   by:  
 Page size